The 3-week NASH mouse, a rapid preclinical model of NASH, to be presented at the Keystone on Obesity and NAFLD Physiogenex will be presenting its innovative 3-week NASH mouse model of NASH - Fibrosis at the Keystone on Obesity and NAFLD in Banff, Alberta, Canada,...
PRECLINICAL CRO SERVICES FOR DRUGS TARGETING METABOLIC DISORDERS
Physiogenex provides preclinical in vivo and ex vivo CRO services with more than 15 years of expertise in evaluating drugs targeting metabolic disorders such as obesity, diabetes, NASH, fibrosis, diabetic nephropathy, cardiovascular complications, dyslipidemia and atherosclerosis.
We develop in-house and gold standard preclinical models in our cutting-edge facilities near Toulouse, France.
Along with our preclinical CRO services, we offer consulting services adapted to the specific needs of our clients. Our metabolic diseases experts offer their many years of experience in drug development to help you design and run efficient and cost-effective studies to shorten your product’s time to market.
STATE OF THE ART CRO FACILITIES
Physiogenex is located near Toulouse (France) in brand new facilities . Our technical platform is equipped with all appropriate devices to ensure high quality CRO services and reliable study results to our clients.
THEY TRUST US
We work with more than 100 biopharmaceutical, nutraceutical and agrifood companies
LATEST NEWS ABOUT PHYSIOGENEX
Physiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type 2 diabetes and related comorbidities (NASH, CKD and CVD), announced the appointment of Natalia Breyner, PhD in Immunology, as Project Manager -...
The SDT fatty rat, a model of diabetic nephropathy, to be presented at the Keystone on Diabetes Physiogenex will be presenting its innovative SDT fatty rat model of diabetic nephropathy at the Keystone conference on Diabetes – glucose control and beyond in Santa Fe,...